Ninlaro
(Ixazomib)ApprovedSmall molecule
TakedaIxazomib is used to treat multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It works by blocking proteins that help cancer cells survive and grow.[2] Ninlaro is currently approved and in use across 26 indications[4].[1]
Ninlaro is one of 586 small molecule programs targeting HIV infection. It is currently in Approved.
26
Indications
94
Total Trials
19
Active Trials
585
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
7
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 26 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Ninlaro
TakedaApproved
Trodelvy
GileadPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Zinecard
CChildren's Oncology Group
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Tricor
JJagotec
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Motexafin Gadolinium
PPharmacyclics LLC.
Preclinical
Iniparib
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma41 trials
Show 38 more trials
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
Completed·—·Phase 2·NCT02412228·12 enrolled
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05722405·100 enrolled
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Completed·—·Phase 2·NCT02916771·61 enrolled
Dexamethasone4 trials
Ixazomib + Pomalidomide + Dexamethasone In MM
Active, not recruiting·—·Phase 1/2·NCT04094961·52 enrolled
Mantle Cell Lymphoma4 trials
Lymphoma4 trials
31 more indications
AL amyloidosis3 trials
Acute Lymphoblastic Leukemia3 trials
PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Active, not recruiting·TTherapeutic Advances in Childhood Leukemia Consortium·Phase 1/2·NCT03817320·24 enrolled
Acute Myeloid Leukemia2 trials
Lenalidomide2 trials
Amyloidosis2 trials
Lung Disease1 trial
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
Terminated·—·Phase 2·NCT04837131·4 enrolled
Macroglobulinemia1 trial
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Completed·—·Phase 2·NCT02400437·26 enrolled
Relapsed/Refractory1 trial
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Terminated·—·Phase 2·NCT04119336·2 enrolled
Renal Cell Carcinoma1 trial
Lupus Nephritis1 trial
Relapsed/Refractory AML1 trial
Kidney Cancer1 trial
Follicular Lymphoma1 trial
Hematologic Malignancies1 trial
Prospective1 trial
Chronic Graft Versus Host Disease1 trial
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.
Active, not recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 1/2·NCT03225417·142 enrolled
Myelodysplastic Syndrome1 trial
Breast Cancer1 trial
Plasmacytoma1 trial
Haematological Malignancy1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Nov 20, 2015
NINLARO
NDA NDA208462
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ninlaro drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ixazomib. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]